Mainstream

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Post ContentroivRead More

You might also be interested in reading The CT blooper reel: our video team’s most unexpected moments of 2020.

February 10, 2025
In Mainstream